Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 7/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024046 | 0.79 | PDE2A (0.32) | SMN1; SMN2 | |
| SCHEMBL6024324 | 0.78 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL6023181 | 0.77 | PDE4A (0.33) | ALDH1A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL14033406 | 0.74 | KMT2A (0.36) | ALDH1A1SMN1; SMN2ACHEMEN1KMT2A | |
| SCHEMBL6024197 | 0.74 | MEN1 (0.33) | SMN1; SMN2MEN1KMT2AMAPTLMNA | |
| SCHEMBL14345864 | 0.73 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2ACHEMEN1KMT2A | |
| SCHEMBL16959674 | 0.72 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2ACHEMEN1KMT2A | |
| SCHEMBL4847783 | 0.71 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL19286922 | 0.71 | ACHE (0.60) | ALDH1A1SMN1; SMN2ACHEMEN1KMT2A | |
| SCHEMBL10821843 | 0.71 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2ACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101900-B2 | Benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-20050187265-A1 | Novel benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides | RHEINHEIMER JOACHIM (DE) | 2005-08-25 | — | — | US | disclosed |
| US-6881742-B1 | Benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187265-A1 | Novel benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides | CBR3, CBR1, CYP1B1 | ALDH1A1 1086/4885SMN1; SMN2 2874/4885ACHE 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.